Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 60

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 60
---
,504,134 |   |     | $             | (204,847 | ) |     | $           | (21,119,151 | ) |     | $     | (5,815,691 | ) |
| Balance                              |     |             | 10,123,771 |     | $      | 1,011 |     |              | 34 |     | $      | - |     |              | 15,007 |     | $      | 2 |     |        | 31,554,704 |     | $      | 3,157 |     |             | 29,338 |     | $      | 3 |     | $          | 15,504,134 |   |     | $             | (204,847 | ) |     | $           | (21,119,151 | ) |     | $     | (5,815,691 | ) |

<div align='center'>The accompanying notes are an integral part of the consolidated financial statements.</div>

| 48 |

<div align='center'>REGEN BIOPHARMA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(unaudited)</div>

|                                           |     | 2025                  
 Three                 
 Months ended June 30, 
 2025                  |          |   |     | 2024 
 2024 |          |   |     | 2025                  
 Nine                  
 Months ended June 30, 
 2025                  |          |   |     | 2024 
 2024 |          |   |
|:------------------------------------------|:----|:----------------------|:---------|:--|:----|:-----|:---------|:--|:----|:----------------------|:---------|:--|:----|:-----|:---------|:--|
| Net                                       
 loss                                      |     | $                     | (167,292 | ) |     | $    | (130,120 | ) |     | $                     | (702,033 | ) |     | $    | (397,507 | ) |
| Other                                     
 comprehensive income, net of tax          |     |                       |          |   |     |      |          |   |     |                       |          |   |     |      |          |   |
| Net                                       
 unrealized gains on investment securities |     |                       | -